Desire, comfort, and sensation all depend on hormones, and on tissue that changes when those hormones fall. Most of what women describe has a physical driver, and most of it responds to treatment.
Reviewed by Allison Mollet, PA-C, MSCP
Updated August 2026
Desire. A persistent loss of interest in sex that a woman notices and is troubled by. The commonest concern, and the one least often asked about.
Comfort. Dryness, burning, tightness, or pain with penetration. Often the first change after menopause.
Sensation and arousal. Less physical response, and less sensitivity than before.
Orgasm. Harder to reach, or weaker.
These overlap. Discomfort reduces desire, and low desire reduces arousal, so a woman rarely has only one of them.
Estrogen. Vaginal tissue depends on it. As estrogen falls the tissue thins, dries, and loses elasticity, which is what produces discomfort and pain. This is genitourinary syndrome of menopause, and it progresses without treatment.
Testosterone. It declines gradually from a woman's twenties, and desire is where its effect is clearest.
The pelvic floor. The muscles behind bladder control also contribute to sensation and orgasm. Childbirth and age weaken them.
Blood flow. Arousal is a vascular event. Thinner tissue with a poorer blood supply responds less.
The rest of the picture. Thyroid disease, iron deficiency, poor sleep, low mood, and some antidepressants all reduce desire. Circumstances matter too, and no treatment substitutes for them.
Women are told this is part of aging and left there. Most of what they describe has a physical driver, and physical drivers are treatable. In our experience the order matters: treat the discomfort first, because desire seldom returns while sex hurts.
— Allison Mollet, PA-C, MSCP
Vaginal estrogen is the direct treatment for dryness and pain. It restores the thickness and blood supply of the tissue, with minimal absorption into the rest of the body.
It works years after menopause, and it can be started before symptoms appear to prevent the thinning rather than treat it.
Where discomfort is the barrier, this is the first thing to fix. Lubricants help with friction, and they do not restore the tissue.
Where symptoms reach beyond the vaginal tissue, estrogen with progesterone treats the wider changes of menopause, and comfort and desire often improve alongside them.
Whether it suits you depends on your history and on where you are relative to menopause. Our benefits of hormone therapy page makes the case, and our forms of hormone therapy page covers the options.
Desire is where the evidence for testosterone in women is strongest. Randomized studies in postmenopausal women support it for low sexual desire that causes distress.
There is no FDA-approved testosterone product for women in the United States, so it is prescribed off-label at female-appropriate doses and monitored with labs.
The dose is a small fraction of a male dose, individualized and adjusted against how you feel. We do not use pellets, because a dose that cannot be adjusted is how testosterone goes wrong in women.
Women also report better energy, steadier mood, and strength that responds to training again. Desire is where the published evidence is strongest, and the rest is what women tell us and what we see.
Emfemme 360 uses radiofrequency to gently warm the vaginal tissue. That increases local blood flow and stimulates new collagen, which improves suppleness, natural lubrication, and comfort.
It is a short series of quick sessions, non-invasive, with no downtime. Our patients report high satisfaction with how they feel afterward.
Emsella strengthens the pelvic floor, which contributes to sensation and orgasm as well as to bladder control. For many women the two treatments together do the most.
Neither involves hormones, which matters for the women who cannot take them.
Low desire usually has more than one cause, so treating one piece of it and stopping is what tends to disappoint. In our experience the tissue, the hormones, and the pelvic floor are assessed together, and the plan addresses whichever of them is actually driving the symptom.
— Allison Mollet, PA-C, MSCP
Thyroid disease, iron deficiency, vitamin D, and sleep all affect desire and energy, and each is treated differently.
Some medications reduce desire, antidepressants among them. That is worth reviewing rather than accepting.
An evaluation looks at these together, which is how we find out which one is driving your symptoms.
Let's begin
An evaluation looks at your hormones, thyroid, metabolic markers, and nutrients together, so the plan treats the cause. An unhurried hour with a Menopause Society Certified Practitioner, in Brea. To speak with us first, call 714-671-2005.
Testosterone for women: what it does and how it's prescribed
Stress incontinence in women: why it happens and what helps
Menopause: what changes, and what helps
The forms of hormone therapy, and how treatment is personalized
Usually more than one thing at once. Falling estrogen makes sex uncomfortable, and falling testosterone reduces desire itself. Thyroid disease, iron deficiency, poor sleep, low mood, and some medications all contribute. An evaluation is how the driver is identified.
Because vaginal tissue depends on estrogen, and without it the tissue thins, dries, and loses elasticity. The clinical name is genitourinary syndrome of menopause. It progresses without treatment, and it responds well to treatment at any point.
For comfort, usually yes, and vaginal estrogen does it directly. Systemic hormone therapy treats the wider changes of menopause, and desire often improves alongside them. Whether it suits you depends on your history.
This is where the evidence is strongest. Randomized studies in postmenopausal women support testosterone for low sexual desire that causes distress. Worth knowing that discomfort with sex needs vaginal estrogen instead, and that low desire usually has more than one cause.
No. There is no FDA-approved testosterone product for women in the United States. It is prescribed off-label at female-appropriate doses, which is a routine and legal part of medical practice, and it is why the dose and the monitoring matter.
Yes. Emfemme improves blood flow and builds new collagen in the tissue, and Emsella strengthens the pelvic floor. Neither involves hormones, and both are options for women who cannot take them or would rather not.
A lubricant reduces friction during sex, which helps in the moment. It does not restore the tissue, so it does not address the underlying change. Vaginal estrogen does, and the two are often used together.
It could be part of it. Some antidepressants reduce desire and make orgasm harder to reach. That is worth reviewing with the prescriber, and it does not rule out a hormonal cause alongside it.
Vaginal estrogen usually improves comfort within a few weeks, and continues to improve over months. Testosterone is assessed over a few months. Emfemme and Emsella work over a short series of sessions.
Desire does change with age, and that is not the same as untreatable. Where a woman notices the change and is troubled by it, there is usually a physical driver, and it is worth evaluating.
Most women come in for how they feel rather than for how they perform. Comfort, lubrication, and desire are what treatment addresses, and improvement in those is what women report.
Sexual symptoms overlap with thyroid disease, iron deficiency, and estrogen deficiency, and each is treated differently. The evaluation is how we tell them apart, and it is why the plan treats the cause.
